Pristimerin

Description: 1. Pristimerin (Celastrol methyl ester) has anticancer activity , treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells. 2. Pristimerin down-regulates the expression of pro-inflammatory mediators through blocking of NF-kappaB activation by inhibiting interconnected ROS/IKK/NF-kappaB signaling pathways, can effectively inhibit both arthritic inflammation and cartilage and bone damage in the joints. Target: Antibacterial, NF-kappaB. Smiles: COC(=O)[C@@]1(C)CC[C@]2(C)CC[C@]3(C)C4=CC=C5C(C)=C(O)C(=O)C=C5[C@]4(C)CC[C@@]3(C)[C@@H]2C1. References: Zuo J , Guo Y , Peng X , et al. Inhibitory action of pristimerin on hypoxia-mediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells[J]. Oncology Reports, 2015, 33(3):1388-94.